Skip to content
10-Q

Quarterly Report

Taysha Gene Therapies, Inc. TSHA

0001193125-26-207666

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 287.36M sh
Shares Diluted Q1 2026 · Mar 31, 2026 366.63M sh
Shares Diluted Q1 2026 · Mar 31, 2025 269.31M sh
Capex Q1 2026 · Mar 31, 2026 $24K
Capex Q1 2026 · Mar 31, 2025 $378K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$40.88M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$22.02M
Long Term Debt Q1 2026 · Mar 31, 2026 $48.96M
Long Term Debt Q1 2026 · Dec 31, 2025 $50.11M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $276.58M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $319.77M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $116.59M
Stockholders Equity Q1 2026 · Mar 31, 2026 $211.94M
Stockholders Equity Q1 2026 · Dec 31, 2025 $246.94M
Stockholders Equity Q1 2026 · Mar 31, 2025 $55.06M
Stockholders Equity Q1 2026 · Dec 31, 2024 $71.53M
Current Liabilities Q1 2026 · Mar 31, 2026 $20.1M
Current Liabilities Q1 2026 · Dec 31, 2025 $26.55M
Total Liabilities Q1 2026 · Mar 31, 2026 $88.41M
Total Liabilities Q1 2026 · Dec 31, 2025 $96.38M
Current Assets Q1 2026 · Mar 31, 2026 $282.25M
Current Assets Q1 2026 · Dec 31, 2025 $324.65M
Total Assets Q1 2026 · Mar 31, 2026 $300.35M
Total Assets Q1 2026 · Dec 31, 2025 $343.32M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.12
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.08
Eps Basic Q1 2026 · Mar 31, 2026 −$0.12
Eps Basic Q1 2026 · Mar 31, 2025 −$0.08
Sga Expense Q1 2026 · Mar 31, 2026 $9.68M
Sga Expense Q1 2026 · Mar 31, 2025 $8.16M
Rd Expense Q1 2026 · Mar 31, 2026 $33.81M
Rd Expense Q1 2026 · Mar 31, 2025 $15.57M
Net Income Q1 2026 · Mar 31, 2026 −$42.41M
Net Income Q1 2026 · Mar 31, 2025 −$21.53M
Operating Income Q1 2026 · Mar 31, 2026 −$43.49M
Operating Income Q1 2026 · Mar 31, 2025 −$21.42M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $2.3M